XTX Topco’s Elicio Therapeutics ELTX Stock Holding History

XTX Topco’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,785	Closed	-$147K	–	4283
2026 Q1	$147K	Buy	+13,785	New	+$133K	﹤0.01%	2961
2022 Q1	–	Sell	-1,006	Closed	-$29K	–	739
2021 Q4	$29K	Buy	+1,006	New	+$50.9K	0.02%	607

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

XTX Topco's ELTX Position: Q2 2026 in Review

XTX Topco sold out of Elicio Therapeutics (ELTX) in Q2 2026, closing a stake of 13,785 shares — an estimated $147K sold.

XTX Topco first reported a position in ELTX in Q4 2021 and held it in 2 quarters. The position peaked at $147K in Q1 2026. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

XTX Topco reported no remaining Elicio Therapeutics position as of Q2 2026 after selling out during the quarter.
XTX Topco sold 13,785 Elicio Therapeutics shares in Q2 2026, an estimated $147K.
XTX Topco first reported a position in Elicio Therapeutics in Q4 2021 and held it in 2 quarters.
XTX Topco's Elicio Therapeutics position peaked at $147K in Q1 2026.
48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.